ArticleActa diabetologica2026
Advanced hybrid closed-loop therapy for type 1 diabetes in a correctional facility: a real-world case series.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of type 1 diabetes (T1D) in correctional facilities is challenging due to limited autonomy, restricted access to technologies, and non-flexible daily routines.
objectiveTo evaluate the feasibility and short-term glycemic outcomes of advanced hybrid closed-loop (aHCL) systems in individuals with T1D in a correctional setting.
methodsWe conducted a retrospective real-world case series including adults with T1D incarcerated in a correctional facility and initiated on an advanced hybrid closed-loop (aHCL) system. Glycemic metrics were assessed at baseline and after 3 months. Continuous variables are reported as median (IQR). Paired comparisons were performed using the Wilcoxon signed-rank test.
resultsSix individuals were included and five completed follow-up. Median HbA1c decreased from 9.7% to 7.8% (p = 0.043). Median time in range (TIR) increased from 41% to 49%, while time below range (TBR) and time above range (TAR) decreased from 0.5% to 0% and from 57.5% to 43%, respectively, although these changes were not statistically significant. No severe hypoglycemia or diabetic ketoacidosis events occurred.
conclusionsUse of aHCL systems in a correctional setting was feasible and associated with improved HbA1c without increased hypoglycemia. These findings support the potential role of advanced diabetes technologies in restricted environments.
Indexed as
Identifiers
42671562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.